284 related articles for article (PubMed ID: 22701724)
1. Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene.
Tanic M; Yanowsky K; Rodriguez-Antona C; Andrés R; Márquez-Rodas I; Osorio A; Benitez J; Martinez-Delgado B
PLoS One; 2012; 7(6):e38847. PubMed ID: 22701724
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA profiling differentiates colorectal cancer according to KRAS status.
Mosakhani N; Sarhadi VK; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S
Genes Chromosomes Cancer; 2012 Jan; 51(1):1-9. PubMed ID: 21922590
[TBL] [Abstract][Full Text] [Related]
3. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
4. miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer.
Letelier P; García P; Leal P; Álvarez H; Ili C; López J; Castillo J; Brebi P; Roa JC
Int J Clin Exp Pathol; 2014; 7(5):1849-67. PubMed ID: 24966896
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors.
Jiao LR; Frampton AE; Jacob J; Pellegrino L; Krell J; Giamas G; Tsim N; Vlavianos P; Cohen P; Ahmad R; Keller A; Habib NA; Stebbing J; Castellano L
PLoS One; 2012; 7(2):e32068. PubMed ID: 22384141
[TBL] [Abstract][Full Text] [Related]
6. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status.
Dacic S; Kelly L; Shuai Y; Nikiforova MN
Mod Pathol; 2010 Dec; 23(12):1577-82. PubMed ID: 20818338
[TBL] [Abstract][Full Text] [Related]
7. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells.
Hara T; Jones MF; Subramanian M; Li XL; Ou O; Zhu Y; Yang Y; Wakefield LM; Hussain SP; Gaedcke J; Ried T; Luo J; Caplen NJ; Lal A
Oncotarget; 2014 Sep; 5(17):7635-50. PubMed ID: 25245095
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
10. Role of miR-143 targeting KRAS in colorectal tumorigenesis.
Chen X; Guo X; Zhang H; Xiang Y; Chen J; Yin Y; Cai X; Wang K; Wang G; Ba Y; Zhu L; Wang J; Yang R; Zhang Y; Ren Z; Zen K; Zhang J; Zhang CY
Oncogene; 2009 Mar; 28(10):1385-92. PubMed ID: 19137007
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells.
Nakano H; Yamada Y; Miyazawa T; Yoshida T
Int J Oncol; 2013 Jun; 42(6):1875-82. PubMed ID: 23588298
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome sequencing analysis reveals miR-30c-5p promotes ferroptosis in cervical cancer and inhibits growth and metastasis of cervical cancer xenografts by targeting the METTL3/KRAS axis.
Gong Y; Luo G; Zhang S; Chen Y; Hu Y
Cell Signal; 2024 May; 117():111068. PubMed ID: 38286198
[TBL] [Abstract][Full Text] [Related]
13. Oral squamous cell carcinoma: microRNA expression profiling and integrative analyses for elucidation of tumourigenesis mechanism.
Manikandan M; Deva Magendhra Rao AK; Arunkumar G; Manickavasagam M; Rajkumar KS; Rajaraman R; Munirajan AK
Mol Cancer; 2016 Apr; 15():28. PubMed ID: 27056547
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer.
Lyu S; Yu Q; Ying G; Wang S; Wang Y; Zhang J; Niu Y
Int J Oncol; 2014 Jan; 44(1):229-37. PubMed ID: 24172884
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-326 inhibits melanoma progression by targeting KRAS and suppressing the AKT and ERK signalling pathways.
Kang K; Zhang J; Zhang X; Chen Z
Oncol Rep; 2018 Jan; 39(1):401-410. PubMed ID: 29115540
[TBL] [Abstract][Full Text] [Related]
16. Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer.
Hashimoto Y; Akiyama Y; Yuasa Y
PLoS One; 2013; 8(5):e62589. PubMed ID: 23667495
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
Heinzelmann J; Unrein A; Wickmann U; Baumgart S; Stapf M; Szendroi A; Grimm MO; Gajda MR; Wunderlich H; Junker K
Ann Surg Oncol; 2014 Mar; 21(3):1046-54. PubMed ID: 24242678
[TBL] [Abstract][Full Text] [Related]
20. miR-200c inhibits breast cancer proliferation by targeting KRAS.
Song C; Liu LZ; Pei XQ; Liu X; Yang L; Ye F; Xie X; Chen J; Tang H; Xie X
Oncotarget; 2015 Oct; 6(33):34968-78. PubMed ID: 26392416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
